The FDA has also cleared the Dexcom G7, Freestyle Libre 2 Plus and Libre 3 CGMs, as well as interoperable CGMs (which can integrate with insulin pumps from various manufacturers), for integration with certain insulin pumps
References Kommu S., & Whitfield P
Tirzepatide is the first dual GLP-1/GIP receptor co-agonist which has been approved for treatment of type 2 diabetes mellitus (T2DM) based on the findings from the SURPASS program
With logistical details completely managed, patients are free to dedicate all of their mental and physical energy toward their recovery, weight goals, and structural healing
Consultations include a full comorbidity assessment, contraindication screening, and a 12-month titration plan
Effects of an Oroxylum indicum Extract (Sabroxy) on Cognitive Function in Adults With Self-reported Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Study